Does sildenafil decrease BP? Yes, sildenafil does lower blood pressure modestly in most users. As a phosphodiesterase type 5 (PDE5) inhibitor, sildenafil causes vasodilation—widening of blood vessels—which typically reduces systolic blood pressure by 8–10 mmHg and diastolic pressure by 5–6 mmHg. Whilst this effect is generally mild and clinically insignificant in healthy individuals, it becomes critically important when sildenafil is combined with nitrates or certain other medications, potentially causing severe hypotension. Understanding how sildenafil affects blood pressure is essential for safe use, particularly in patients with cardiovascular conditions or those taking multiple medications.

How Sildenafil Affects Blood Pressure

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily prescribed for erectile dysfunction and pulmonary arterial hypertension. The drug works by inhibiting the PDE5 enzyme, which leads to increased levels of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This biochemical cascade causes relaxation of vascular smooth muscle, resulting in vasodilation—the widening of blood vessels throughout the body.

When blood vessels dilate, peripheral vascular resistance decreases, which typically leads to a modest reduction in blood pressure. In most healthy individuals taking sildenafil for erectile dysfunction at standard doses (25–100 mg), this effect is generally mild and clinically insignificant. According to the UK Summary of Product Characteristics (SmPC), sildenafil commonly produces a small decrease in both systolic and diastolic blood pressure, usually in the range of 8–10 mmHg systolic and 5–6 mmHg diastolic pressure reduction. These changes occur approximately one hour after administration, coinciding with peak plasma concentrations of the medication.

The vasodilatory effect of sildenafil is not limited to the corpus cavernosum (the erectile tissue of the penis) but affects blood vessels throughout the systemic circulation. This is why sildenafil is contraindicated in patients with hypotension (blood pressure <90/50 mmHg) and in those for whom sexual activity is inadvisable due to underlying cardiovascular conditions. The blood pressure-lowering effect is generally transient, lasting several hours as the drug is metabolised and eliminated from the body. For individuals with normal baseline blood pressure and no contraindicated medications, this modest hypotensive effect rarely causes problematic symptoms. However, alcohol consumption can increase the likelihood of postural hypotension and dizziness. Understanding this mechanism is essential for safe prescribing and patient counselling, particularly in those with pre-existing cardiovascular conditions or those taking multiple antihypertensive medications.

Blood Pressure Risks When Taking Sildenafil

Sildenafil is absolutely contraindicated in patients taking any form of nitrates or nitric oxide donors, including glyceryl trinitrate (GTN), isosorbide mononitrate, isosorbide dinitrate, and recreational 'poppers' (amyl nitrite). When sildenafil is combined with these medications, the result can be severe, potentially life-threatening hypotension. Both drug classes work through pathways involving nitric oxide and cGMP, and their combined effect produces profound vasodilation that can cause blood pressure to drop precipitously. This interaction is an absolute contraindication, not a timing issue—patients taking nitrates should not use sildenafil under any circumstances.

Sildenafil is also contraindicated with riociguat, a soluble guanylate cyclase stimulator used for pulmonary hypertension, as this combination can cause severe hypotension.

Additional blood pressure-related risks include:

• Alpha-blocker interactions: Medications such as doxazosin, tamsulosin, and alfuzosin (commonly prescribed for benign prostatic hyperplasia) can cause additive hypotensive effects when combined with sildenafil. According to the BNF, patients should be stable on alpha-blocker therapy before starting sildenafil, which should be initiated at the lowest dose (25 mg). Consider separating doses to minimise the risk of postural hypotension.

• Antihypertensive medication interactions: The SmPC notes that patients taking multiple blood pressure medications may experience enhanced hypotensive effects, though these are generally modest. Careful monitoring is advisable when initiating sildenafil in these individuals.

• Postural hypotension: Some patients may experience dizziness, light-headedness, or syncope (fainting) when standing up quickly after taking sildenafil, particularly if they are dehydrated, have consumed alcohol, or are taking other vasodilating medications.

• Pre-existing cardiovascular disease: Sildenafil is contraindicated in patients with severe cardiovascular conditions, including those who have had a myocardial infarction or stroke within the last 6 months, unstable angina, severe heart failure, severe left ventricular outflow obstruction (e.g., aortic stenosis), or severe hepatic impairment. The Medicines and Healthcare products Regulatory Agency (MHRA) advises caution in these populations, and sexual activity itself may pose cardiovascular risk in such patients.

When to Seek Medical Advice About Sildenafil and Blood Pressure

Patients should contact their GP or healthcare provider before starting sildenafil if they have any history of cardiovascular disease, including hypertension, hypotension (BP <90/50 mmHg), uncontrolled high blood pressure, heart failure, or previous heart attack or stroke. A thorough cardiovascular assessment is essential to determine whether sildenafil is appropriate and safe. Those currently taking any form of nitrate medication, nitric oxide donors (including recreational 'poppers'), or riociguat must inform their doctor, as these represent absolute contraindications to sildenafil use.

Seek immediate medical attention (call 999 or attend A&E) if you experience:

• Severe chest pain or pressure, particularly if accompanied by pain radiating to the arm, jaw, or back

• Sudden severe dizziness or fainting episodes

• Irregular or rapid heartbeat (palpitations) that persists

• Severe shortness of breath or difficulty breathing

• Signs of stroke, including sudden weakness, speech difficulties, or facial drooping

• Sudden vision loss in one or both eyes

• Sudden decrease or loss of hearing

• Prolonged erection lasting more than 4 hours (priapism) – this is a medical emergency

Contact your GP or NHS 111 within 24 hours if you experience:

• Persistent light-headedness or dizziness when standing

• Unusual fatigue or weakness after taking sildenafil

• Headaches that are severe or different from your usual pattern

• Mild visual disturbances or changes in colour perception (a blue tinge to vision is a common side effect)

• Any symptoms that concern you or differ from what you expected

Patients should also consult their healthcare provider before taking sildenafil if they are considering starting new medications, including over-the-counter preparations and herbal supplements, as these may interact with sildenafil or affect blood pressure. Regular medication reviews are important for individuals on multiple medications. According to NICE guidance, patients with erectile dysfunction should receive holistic cardiovascular risk assessment, as erectile dysfunction can be an early marker of cardiovascular disease. This assessment provides an opportunity to optimise blood pressure control and overall cardiovascular health alongside consideration of sildenafil therapy.

If you experience any suspected side effects, report them to the MHRA Yellow Card Scheme, which helps monitor the safety of medicines.

Does Sildenafil Lower Blood Pressure in Clinical Studies?

Clinical trial evidence consistently demonstrates that sildenafil does produce measurable reductions in blood pressure, though the magnitude and clinical significance vary depending on patient population, dose, and concurrent medications. According to the UK Summary of Product Characteristics (SmPC), sildenafil at doses used for erectile dysfunction (50–100 mg) typically reduces systolic blood pressure by approximately 8–10 mmHg and diastolic blood pressure by 5–6 mmHg in healthy volunteers and patients without significant cardiovascular disease.

In patients with pre-existing hypertension, studies have shown similar modest reductions in blood pressure. The BNF and SmPC note that sildenafil generally has small additive effects when used with standard antihypertensive medications, including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics. These effects are rarely clinically significant in appropriately selected patients. Sildenafil is also licensed specifically for pulmonary arterial hypertension (as Revatio) at a dose of 20 mg three times daily, where its vasodilatory properties in the pulmonary circulation are therapeutic, while systemic blood pressure effects remain generally modest.

Research examining sildenafil in patients with controlled hypertension taking antihypertensive medications has generally found the drug to be well-tolerated, with additive blood pressure reductions rarely causing symptomatic hypotension. However, studies have confirmed the dangerous interaction with nitrates, showing profound and prolonged hypotensive effects. Nitrates should not be administered within 24 hours of sildenafil use, and even then only with close haemodynamic monitoring in emergency situations. The European Medicines Agency (EMA) and MHRA product information reflects this evidence base, noting that whilst blood pressure reduction occurs, severe hypotension is uncommon in appropriately selected patients without contraindications.

Key evidence-based conclusions include:

• Sildenafil does lower blood pressure in a dose-dependent manner, but the effect is typically modest in magnitude

• The hypotensive effect is most pronounced approximately one hour post-dose

• Severe hypotension is uncommon when sildenafil is used without contraindicated drugs and in suitable patients

• Patients with well-controlled hypertension can generally use sildenafil safely under medical supervision

• The cardiovascular safety profile supports its use in appropriately selected patients, as confirmed by extensive post-marketing surveillance data

Healthcare professionals should conduct individualised risk-benefit assessments, considering each patient's cardiovascular status, concurrent medications, and overall health profile before prescribing sildenafil.

Frequently Asked Questions